Assessment of the effect of TLR7/8, TLR9 agonists and CD40 ligand on the transformation efficiency of Epstein-Barr virus in human B lymphocytes by limiting dilution assay

Cytotechnology

Volumn 66, Issue 1, 2014, Pages 95-105

  Younesi, Vahid ^a   Shirazi, Forough Golsaz ^a   Memarian, Ali ^a   Amanzadeh, Amir ^b   Jeddi Tehrani, Mahmood ^c   Shokri, Fazel ^a,c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b PASTEUR INSTITUTE OF IRAN   (Iran)

^c AVICENNA RESEARCH INSTITUTE   (Iran)

Author keywords

B lymphocyte; CD40 ligand; Epstein Barr virus; Limiting dilution assay; Proliferation; Toll like receptor; Transformation

Indexed keywords

CD40 LIGAND; RESIQUIMOD; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST;

ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CARCINOGENESIS; CELL ASSAY; CELL DENSITY; CELL STIMULATION; CELL TRANSFORMATION; COMPARATIVE STUDY; CONTROLLED STUDY; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LIMITING DILUTION ASSAY; LYMPHOBLASTOID CELL; LYMPHOCYTE PROLIFERATION; NONHUMAN; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; VIRUS CELL INTERACTION; VIRUS CELL TRANSFORMATION; VIRUS LATENCY; VIRUS LOAD; VIRUS TRANSFORMATION;

HUMAN HERPESVIRUS 4;

EID: 84893636984     PISSN: 09209069     EISSN: 15730778     Source Type: Journal    
DOI: 10.1007/s10616-013-9542-x     Document Type: Article

References (56)

1. Adler B, Schaadt E, Kempkes B, Zimber-Strobl U, Baier B, Bornkamm GW (2002) Control of Epstein-Barr virus reactivation by activated CD40 and viral latent membrane protein 1. Proc Natl Acad Sci USA 99:437-442
2. Ahonen CL, Wasiuk A, Fuse S, Turk MJ, Ernstoff MS, Suriawinata AA, Gorham JD, Kedl RM, Usherwood EJ, Noelle RJ (2008) Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines. Blood 111:3116-3125
3. Bagchi A, Herrup EA, Warren HS, Trigilio J, Shin HS, Valentine C, Hellman J (2007) MyD88-dependent and MyD88-independent pathways in synergy, priming, and tolerance between TLR agonists. J Immunol 178:1164-1171
4. Bekeredjian-Ding I, Jego G (2009) Toll-like receptors-sentries in the B-cell response. Immunology 128:311-323
5. Berghofer B, Haley G, Frommer T, Bein G, Hackstein H (2007) Natural and synthetic TLR7 ligands inhibit CpG-A- and CpG-C-oligodeoxynucleotide-induced IFN-alpha production. J Immunol 178:4072-4079
6. Bird AG, Britton S, Ernberg I, Nilsson K (1981) Characteristics of Epstein-Barr virus activation of human B lymphocytes. J Exp Med 154:832-839
7. Booth JS, Buza JJ, Potter A, Babiuk LA, Mutwiri GK (2010) Co-stimulation with TLR7/8 and TLR9 agonists induce down-regulation of innate immune responses in sheep blood mononuclear and B cells. Dev Comp Immunol 34:572-578
8. Bowie AG, Unterholzner L (2008) Viral evasion and subversion of pattern-recognition receptor signalling. Nat Rev Immunol 8:911-922
9. Brown KD, Hostager BS, Bishop GA (2001) Differential signaling and tumor necrosis factor receptor-associated factor (TRAF) degradation mediated by CD40 and the Epstein-Barr virus oncoprotein latent membrane protein 1 (LMP1). J Exp Med 193:943-954
10. Brown HJ, Song MJ, Deng H, Wu TT, Cheng G, Sun R (2003) NF-kappaB inhibits gammaherpesvirus lytic replication. J Virol 77:8532-8540
11. Chang IC, Wu JY, Lu HI, Ko HW, Kuo JL, Wang CY, Shen PS, Hwang SM (2006) High-potentiality preliminary selection criteria and transformation time-dependent factors analysis for establishing Epstein-Barr virus transformed human lymphoblastoid cell lines. Cell Prolif 39:457-469
12. Gargano LM, Forrest JC, Speck SH (2009) Signaling through Toll-like receptors induces murine gammaherpesvirus 68 reactivation in vivo. J Virol 83:1474-1482
13. Gaudreault E, Fiola S, Olivier M, Gosselin J (2007) Epstein-Barr virus induces MCP-1 secretion by human monocytes via TLR2. J Virol 81:8016-8024
14. Gorden KK, Qiu X, Battiste JJ, Wightman PP, Vasilakos JP, Alkan SS (2006) Oligodeoxynucleotides differentially modulate activation of TLR7 and TLR8 by imidazoquinolines. J Immunol 177:8164-8170
15. Guggemoos S, Hangel D, Hamm S, Heit A, Bauer S, Adler H (2008) TLR9 contributes to antiviral immunity during gammaherpesvirus infection. J Immunol 180:438-443
16. Hartmann G, Krieg AM (2000) Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol 164:944-953
17. Henderson E, Miller G, Robinson J, Heston L (1977) Efficiency of transformation of lymphocytes by Epstein-Barr virus. Virology 76:152-163
18. Hiscott J, Kwon H, Genin P (2001) Hostile takeovers: viral Approperiation of the NF-kB pathway. J Clin Invest 107:141-151
19. Hur DY, Lee MH, Kim JW, Kim JH, Shin YK, Rho JK, Kwack KB, Lee WJ, Han BG (2005) CD19 signalling improves the Epstein-Barr virus-induced immortalization of human B cell. Cell Prolif 38:35-45
20. Imadome K, Shirakata M, Shimizu N, Nonoyama S, Yamanashi Y (2003) CD40 ligand is a critical effector of Epstein-Barr virus in host cell survival and transformation. Proc Natl Acad Sci USA 100:7836-7840
21. Iskra S, Kalla M, Delecluse HJ, Hammerschmidt W, Moosmann A (2010) Toll-like receptor agonists synergistically increase proliferation and activation of B cells by epstein-barr virus. J Virol 84:3612-3623
22. Kazemi T, Asgarian-Omran H, Hojjat-Farsangi M, Shabani M, Memarian A, Sharifian RA, Razavi SM, Jeddi-Tehrani M, Rabbani H, Shokri F (2008) Fc receptor-like 1-5 molecules are similarly expressed in progressive and indolent clinical subtypes of B-cell chronic lymphocytic leukemia. Int J Cancer 123:2113-2119
23. Kuppers R (2003) B cells under influence: transformation of B cells by Epstein-Barr virus. Nat Rev Immunol 3:801-812
24. Ladell K, Dorner M, Zauner L, Berger C, Zucol F, Bernasconi M, Niggli FK, Speck RF, Nadal D (2007) Immune activation suppresses initiation of lytic Epstein-Barr virus infection. Cell Microbiol 9:2055-2069
25. Laherty CD, Hu HM, Opipari AW, Wang F, Dixit VM (1992) The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor kappa B. J biolog chem 267:24157-24160
26. Ma R, Du JL, Huang J, Wu CY (2007) Additive effects of CpG ODN and R-848 as adjuvants on augmenting immune responses to HBsAg vaccination. Biochem Biophys Res Commun 361:537-542
27. Mancao C, Hammerschmidt W (2007) Epstein-Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival. Blood 110:3715-3721
28. Manor E (2008) Human plasma accelerates immortalization of B lymphocytes by Epstein-Barr virus. Cell Prolif 41:292-298
29. Marshall JD, Heeke DS, Gesner ML, Livingston B, Van Nest G (2007) Negative regulation of TLR9-mediated IFN-alpha induction by a small-molecule, synthetic TLR7 ligand. J Leukoc Biol 82:497-508
30. Martin HJ, Lee JM, Walls D, Hayward SD (2007) Manipulation of the toll-like receptor 7 signaling pathway by Epstein-Barr virus. J Virol 81:9748-9758
31. Megyeri K, Au WC, Rosztoczy I, Raj NB, Miller RL, Tomai MA, Pitha PM (1995) Stimulation of interferon and cytokine gene expression by imiquimod and stimulation by Sendai virus utilize similar signal transduction pathways. Mol Cell Biol 15:2207-2218
32. Middeldorp JM, Brink AA, van den Brule AJ, Meijer CJ (2003) Pathogenic roles for Epstein-Barr virus (EBV) gene products in EBV-associated proliferative disorders. Crit Rev Oncol Hematol 45:1-36
33. Mossman KL, Ashkar AA (2005) Herpesviruses and the innate immune response. Viral Immunol 18:267-281
34. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A (2005) Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 6:769-776
35. Oeckinghaus A, Hayden MS, Ghosh S (2011) Crosstalk in NF-kappaB signaling pathways. Nat Immunol 12:695-708
36. Oh HM, Oh JM, Choi SC, Kim SW, Han WC, Kim TH, Park DS, Jun CD (2003) An efficient method for the rapid establishment of Epstein-Barr virus immortalization of human B lymphocytes. Cell Prolif 36:191-197
37. Pasha RP, Shokrgozar MA, Bahrami ZS, Shokri F (2004) Frequency analysis of B lymphocytes specific for Rh antigens in naturally immunized Rh-negative women. Vox Sang 86:62-70
38. Pelloquin F, Lamelin JP, Lenoir GM (1986) Human B lymphocytes immortalization by Epstein-Barr virus in the presence of cyclosporin A. In Vitro Cell Dev Biol 22:689-694
39. Pokrovskaja K, Ehlin-Henriksson B, Kiss C, Challa A, Gordon J, Gogolak P, Klein G, Szekely L (2002) CD40 ligation downregulates EBNA-2 and LMP-1 expression in EBV-transformed lymphoblastoid cell lines. Int J Cancer 99:705-712
40. Quan TE, Roman RM, Rudenga BJ, Holers VM, Craft JE (2010) Epstein-Barr virus promotes interferon-alpha production by plasmacytoid dendritic cells. Arthritis Rheum 62:1693-1701
41. Rastelli J, Homig-Holzel C, Seagal J, Muller W, Hermann AC, Rajewsky K, Zimber-Strobl U (2008) LMP1 signaling can replace CD40 signaling in B cells in vivo and has unique features of inducing class-switch recombination to IgG1. Blood 111:1448-1455
42. Roda JM, Parihar R, Carson WE 3rd (2005) CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells. J Immunol 175:1619-1627
43. Roelofs MF, Joosten LA, Abdollahi-Roodsaz S, van Lieshout AW, Sprong T, van den Hoogen FH, van den Berg WB, Radstake TR (2005) The expression of toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells. Arthritis Rheum 52:2313-2322
44. Shokrgozar MA, Shokri F (2001) Enumeration of hepatitis B surface antigen-specific B lymphocytes in responder and non-responder normal individuals vaccinated with recombinant hepatitis B surface antigen. Immunology 104:75-79
45. Shokri F, Mageed RA, Maziak BR, Jefferis R (1991) Expression of VHIII-associated cross-reactive idiotype on human B lymphocytes. Association with staphylococcal protein A binding and Staphylococcus aureus Cowan I stimulation. J Immunol 146:936-940
46. Sivori S, Falco M, Della Chiesa M, Carlomagno S, Vitale M, Moretta L, Moretta A (2004) CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells. Proc Natl Acad Sci USA 101:10116-10121
47. Stenfors LE, Raisanen S (1993) The membranous tonsillitis during infectious mononucleosis is nevertheless of bacterial origin. Int J Pediatr Otorhinolaryngol 26:149-155
48. Tomai MA, Gibson SJ, Imbertson LM, Miller RL, Myhre PE, Reiter MJ, Wagner TL, Tamulinas CB, Beaurline JM, Gerster JF et al (1995) Immunomodulating and antiviral activities of the imidazoquinoline S-28463. Antiviral Res 28:253-264
49. Tosato G, Steinberg AD, Yarchoan R, Heilman CA, Pike SE, De Seau V, Blaese RM (1984) Abnormally elevated frequency of Epstein-Barr virus-infected B cells in the blood of patients with rheumatoid arthritis. J Clin Investig 73:1789-1795
50. Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, Gismondo MR, Murphy BR, Rappuoli R, Lanzavecchia A (2004) An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med 10:871-875
51. Unterholzner L, Bowie AG (2008) The interplay between viruses and innate immune signaling: recent insights and therapeutic opportunities. Biochem Pharmacol 75:589-602
52. Wagner M, Poeck H, Jahrsdoerfer B, Rothenfusser S, Prell D, Bohle B, Tuma E, Giese T, Ellwart JW, Endres S, Hartmann G (2004) IL-12p70-dependent Th1 induction by human B cells requires combined activation with CD40 ligand and CpG DNA. J Immunol 172:954-963
53. Yarchoan R, Tosato G, Blaese RM, Simon RM, Nelson DL (1983) Limiting dilution analysis of Epstein-Barr virus-induced immunoglobulin production by human B cells. J Exp Med 157:1-14
54. Younesi V, Nikzamir H, Yousefi M, Khoshnoodi J, Arjmand M, Rabbani H, Shokri F (2010) Epstein Barr virus inhibits the stimulatory effect of TLR7/8 and TLR9 agonists but not CD40 ligand in human B lymphocytes. Microbiol Immunol 54:534-541
55. Young LS, Rickinson AB (2004) Epstein-Barr virus: 40 years on. Nat Rev Cancer 4:757-768
56. Zheng R, Cohen PA, Paustian CA, Johnson TD, Lee WT, Shu S, Koski GK (2008) Paired Toll-like receptor agonists enhance vaccine therapy through induction of interleukin-12. Cancer Res 68:4045-4049